Scynexis SCYX
NASDAQ SCYX
$4.91 -0.24 (-4.66%)
At close: Sep 9, 2026 · 4:00 PM EDT

Scynexis (SCYX) Long-Term Investments (2016 - 2026)

Scynexis' (SCYX) quarterly Long-Term Investments came in at $17.0 million in Q2 2026, up 881.97% on a YoY basis from $1.7 million in Q2 2025, and up 29.61% quarter-over-quarter from $13.2 million in Q1 2026.

Analysis

Scynexis (SCYX) Long-Term Investments (2016 - 2026) Analysis & Trends

Scynexis (SCYX) has reported Long-Term Investments for 5 consecutive years, with $17.0 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Long-Term Investments rose 881.97% year-over-year to $17.0 million; the trailing twelve-month figure through Jun 2026 stood at $17.0 million (up 881.97% YoY), and the FY2025 full-year result was $16.2 million, up 2.53% from the prior year.
  • Long-Term Investments rose to $17.0 million in Q2 2026 per SCYX's latest filing, from $13.2 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $23.6 million in Q4 2023 and bottomed at $1.7 million in Q2 2025.
  • Historically, Long-Term Investments has averaged $13.7 million across 4 years, with a median of $14.9 million in 2024.
  • The sharpest annual moves came in 2025 and 2026: Long-Term Investments plunged 83.71% in 2025, then soared 881.97% in 2026.
  • Over 4 years, Long-Term Investments stood at $23.6 million in 2023, then sank by 32.84% to $15.8 million in 2024, then advanced by 2.53% to $16.2 million in 2025, then climbed by 4.92% to $17.0 million in 2026.
  • According to Business Quant data, Long-Term Investments over the past three periods registered $17.0 million, $13.2 million, and $16.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Investments (Qtr)
1 Amgen 211.73 Bn 197.74 Bn 7.24 Bn -
2 Gilead Sciences 180.92 Bn 177.74 Bn 6.22 Bn -
3 Vertex Pharmaceuticals 132.16 Bn 124.30 Bn 2.84 Bn 5.79 Bn
4 Regeneron Pharmaceuticals 82.89 Bn 74.90 Bn 3.93 Bn 9.83 Bn
5 Argenx Se 61.41 Bn 56.23 Bn 1.37 Bn -4.00 Mn
6 Moderna 53.99 Bn 48.85 Bn 52.00 Mn 1.77 Bn
7 Alnylam Pharmaceuticals 34.48 Bn 31.18 Bn 992.69 Mn 22.17 Mn
8 Biogen 31.15 Bn 29.86 Bn 1.96 Bn -
9 Roivant Sciences 30.05 Bn 30.05 Bn 1.16 Mn -
10 Scynexis 58.41 Mn -56.29 Mn - 17.05 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 17.05 Mn
Mar 31, 2026 13.15 Mn
Dec 31, 2025 16.25 Mn
Jun 30, 2025 1.74 Mn
Mar 31, 2025 13.16 Mn
Dec 31, 2024 15.85 Mn
Sep 30, 2024 16.12 Mn
Jun 30, 2024 10.66 Mn
Mar 31, 2024 13.94 Mn
Dec 31, 2023 23.59 Mn
Sep 30, 2023 17.12 Mn
Jun 30, 2023 6.34 Mn
Sep 30, 2016 6.03 Mn